The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib

Abstract

These findings implicate the JAK/STAT pathway in systemic sclerosis skin and lung fibrosis and identify tofacitinib as a potential antifibrotic agent for the treatment of systemic sclerosis and other fibrotic diseases.